Cannita, K., Paradisi, S., Cocciolone, V., Bafile, A., Rinaldi, L., Irelli, A., . . . Ficorella, C. (2016). New schedule of bevacizumab/paclitaxel as first‐line therapy for metastatic HER2‐negative breast cancer in a real‐life setting. Cancer Med.
Chicago-стиль цитированияCannita, Katia, et al. "New Schedule of Bevacizumab/paclitaxel As First‐line Therapy for Metastatic HER2‐negative Breast Cancer in a Real‐life Setting." Cancer Med 2016.
MLA-цитированиеCannita, Katia, et al. "New Schedule of Bevacizumab/paclitaxel As First‐line Therapy for Metastatic HER2‐negative Breast Cancer in a Real‐life Setting." Cancer Med 2016.
Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.